Stay updated on Mepolizumab SC 100mg in Severe Eosinophilic Asthma Clinical Trial

Sign up to get notified when there's something new on the Mepolizumab SC 100mg in Severe Eosinophilic Asthma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mepolizumab SC 100mg in Severe Eosinophilic Asthma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and efficacy evaluation of Mepolizumab 100 mg SC in Indian participants aged 18 years or above with severe eosinophilic asthma.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:20.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific health conditions or prior treatments. This change provides more context and examples of the criteria used for participant selection in clinical studies.
    Difference
    44%
    Check dated 2024-05-22T21:38:11.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:23:38.000Z thumbnail image

Stay in the know with updates to Mepolizumab SC 100mg in Severe Eosinophilic Asthma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mepolizumab SC 100mg in Severe Eosinophilic Asthma Clinical Trial page.